Research Progress of Proteasome Inhibitor MG132 in Treatment of Gynecologic Malignant Tumors

ABSTRACT

The ubiquitin‐proteasome system (UPS) is the primary mechanism for intracellular protein degradation, crucial in oncogenesis and tumor progression. Proteasome inhibitors disrupt UPS‐mediated proteolysis, effectively inhibiting neoplastic cell proliferation, and have become established therapeutic targets in oncology. Gynecologic malignant tumors pose a significant threat to women's reproductive health globally. Among proteasome inhibitors, MG132 has garnered extensive attention in gynecologic oncology due to its multifaceted mechanisms, including cell cycle regulation, NF‐κB signaling inhibition, and modulation of p53 activity. This review consolidates recent research on the therapeutic potential of MG132 in gynecologic malignant tumors, with a focus on its molecular mechanisms of action.